The Effect of PPB Using 10, 20 and 30 ml of Lidocaine, Study on Volunteers
Primary Purpose
Knee Arthritis, Anesthesia, Local, Post Surgical Pain
Status
Not yet recruiting
Phase
Phase 4
Locations
Denmark
Study Type
Interventional
Intervention
Lidocaine Hydrochloride 10 MG/ML [Xylocaine]
Lidocaine Hydrochloride 10 MG/ML [Xylocaine]
Lidocaine Hydrochloride 10 MG/ML [Xylocaine]
Lidocaine Hydrochloride 10 MG/ML [Xylocaine]
Lidocaine Hydrochloride 10 MG/ML [Xylocaine]
Sponsored by
About this trial
This is an interventional treatment trial for Knee Arthritis
Eligibility Criteria
Inclusion Criteria:
- ASA 1-2
- Ability to give their written informed consent to participating in the study after having fully understood the contents of the study
Exclusion Criteria:
- Subjects who cannot cooperate with the study.
- Subjects who cannot understand or speak Danish.
- Subjects with allergy to the medicines used in the study.
- Subjects suffering from alcohol and/or drug abuse - based on the investigator's opinion.
- Pathology or previous surgery to the lower limb.
- Intake of any analgesics 24 hours prior to baseline measurements.
- BMI > 30
- Pregnancy status, provided by the volunteer.
Sites / Locations
- Elective Surgery Center at Silkeborg Regional Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm Type
Experimental
Experimental
Experimental
Active Comparator
Active Comparator
Arm Label
Group A
Groups B
Group C
Group FNB
Groups SNB
Arm Description
Popliteal Plexus Block given with 10 ml of Lidocaine Hydrochloride 10 mg/ml
Popliteal Plexus Block given with 20 ml of Lidocaine Hydrochloride 10 mg/ml
Popliteal Plexus Block given with 30 ml of Lidocaine Hydrochloride 10 mg/ml
Femoral Nerve Block given with 20 ml of Lidocaine Hydrochloride 10 mg/ml
Sciatic Nerve Block given with 20 ml og Lidocaine Hydrochloride 10 mg/ml
Outcomes
Primary Outcome Measures
MVIC (Maximum Voluntary Isometric Contraction) ankle plantarflexion
Difference between group A, B and C in post block MVIC by ankle plantarflexion, expressed as percentage change of the pre block value. MVIC is measured using a handheld dynamometer.
MVIC ankle dorsiflexion
Difference between group A, B and C in post block MVIC by ankle dorsiflexion, expressed as a percentage change of the pre block value. MVIC is measured using a handheld dynamometer.
Secondary Outcome Measures
MVIC knee extension
Difference between group A, B and C in post block MVIC by knee extension, expressed as a percentage change of the pre block value. MVIC is measured using a handheld dynamometer.
cMAP (compoud motor action potention) gatrocnemius
Difference between group A, B and C, in the number of volunteers with affected cMAP of the gastrocnemius muscle, defined as sufficient change from pre block to post block. Cut-off value for sufficient change is determined by SNB group. cMAP is recorded using a motor nerve conduction study.
cMAP tibialis anterior
Difference between group A, B and C, in the number of volunteers with affected cMAP of the tibialis anterior muscle, defined as sufficient change from pre block to post block. Cut-off value for sufficient change is determined by SNB group. cMAP is recorded using a motor nerve conduction study.
cMAP vastus medialis
Difference between group A, B and C, in the number of volunteers with affected cMAP of the vastus medialis muscle, defined as sufficient change from pre block to post block. Cut-off value for sufficient change is determined by FNB group. cMAP is recorded using a motor nerve conduction study.
cMAP vastus lateralis
Difference between group A, B and C, in the number of volunteers with affected cMAP of the vastus lateralis muscle, defined as sufficient change from pre block to post block. Cut-off value for sufficient change is determined by FNB group. cMAP is recorded using a motor nerve conduction study.
Saphenus senory test
Difference between group A, B and C in the number of volunteers with an affected sensory of the saphenous nerve, defined as change, from pre block to post block, in the volunteers ability to discriminate cold in the cutaneous area innervated by the medial crural cutaneous branches of saphenous nerve.
Full Information
NCT ID
NCT05464862
First Posted
July 5, 2022
Last Updated
July 14, 2022
Sponsor
Charlotte Runge
Collaborators
Danish Society of Anesthesiology and Intensive Care Medicine DASAIM, University of Aarhus, The Danish Rheumatism Association
1. Study Identification
Unique Protocol Identification Number
NCT05464862
Brief Title
The Effect of PPB Using 10, 20 and 30 ml of Lidocaine, Study on Volunteers
Official Title
The Effect of the Popliteal Plexus Block on the Motor Function of the Leg - a Randomized, Controlled, Blinded Study in Volunteers
Study Type
Interventional
2. Study Status
Record Verification Date
July 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
September 2022 (Anticipated)
Primary Completion Date
September 2025 (Anticipated)
Study Completion Date
September 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Charlotte Runge
Collaborators
Danish Society of Anesthesiology and Intensive Care Medicine DASAIM, University of Aarhus, The Danish Rheumatism Association
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of this study is to evaluate the Popliteal Plexus Block (PPB) effect on motor nerve branches of the sciatic and femoral nerve, when using different volumes of local anesthetics for PPB.
The hypothesis is that increasing the volume of anesthetics used for PPB will spread to the sciatic nerve leading to a reduced muscle strength in the lower leg and decreased nerve conduction velocity in the nerve to gastrocnemius muscle (the tibial nerve) and the nerve to anterior tibial muscle (the deep fibular nerve).
The effects will be evaluated by maximum voluntary isometric contraction (MVIC) of the lower leg muscles and by recordings of the compound muscle action potential (cMAP) of the gastrocnemius and tibialis anterior muscles - a motor nerve conduction study.
In addition, evaluation of PPBs effect on the femoral nerve is done by MVIC of the quadriceps femoris muscle, cMAP of the vastus medialis and vastus lateralis muscles and by a sensory nerve conduction study of the saphenous nerve.
Detailed Description
A total number of 40 volunteers will be enrolled in the study. Each volunteer will receive two peripheral nerve blocks (one in each leg) on the day of participation. This will result in 80 peripheral nerve blocks. The types of nerve blocks given to each leg on each volunteer will depend on randomization.
The 80 nerve blocks are divided into five groups specified by type of nerve block, volume of anesthetic used, and respective numbers of legs used in the group. The groups and specifications are listed here:
Groups name, type of peripheral nerve block, study medication dosage and number of legs in the group:
Group A: PPB with 10 ml of lidocaine 1%, 20 legs.
Group B: PPB with 20 ml of lidocaine 1%, 20 legs.
Group C: PPB with 30 ml of lidocaine 1%, 20 legs.
Group FNB: FNB with 20 ml of lidocaine 1%, 10 legs.
Group SNB: SNB with 20 ml of lidocaine 1%, 10 legs.
Group FNB of SNB are performed unblinded and works as active comparatives for model control, in order to establish reference points for when a nerve is considered affected.
Prior to nerve block procedure , pre block assessments are obtained in the following order:
Sensory test of the saphenous nerve.
MVIC by ankle plantarflexion.
MVIC by ankle dorsiflexion.
MVIC by knee extension.
Compound muscle action potential (cMAP) recordings in the following order:
Nerve to vastus medialis muscle
Nerve to vastus lateralis muscle
Nerve to tibialis anterior muscle
Nerve to gastrocnemius muscle
60 minutes after the block performance, post block assessments are done. Values are obtained in the same order as for the pre block assessments.
A peripheral intravenous line is inserted prior to the procedure of the peripheral nerve block is performed. At the discretion of the anesthetist, up to 20 mg Propofol IV may be provided to ease the patient during the nerve block procedure. The volunteer is monitored with continuous electrocardiography and pulse oximetry for the first 30 minutes after block performance and clinically hereafter. Final check by an investigator to ensure the volunteer is ready to go home. If the muscle strength is reduced, the volunteer will not be sent home before the ability to walk safely with crutches is ensured.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Knee Arthritis, Anesthesia, Local, Post Surgical Pain
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
A person, not otherwise involved in the study will perform a randomization list. The list will contain the ID number (1-40), assigned group and type of nerve block and volume of Lidocaine 1% to be administered for nerve block, e.g.
ID nr. 1: Right leg = Group A, PPB with 10 ml of lidocaine 1% Left leg = Group SNB, SNB with 20 ml of lidocaine 1%
Randomization must ensure that the legs of a volunteer cannot be assigned to the same group.
Groups name, type of peripheral nerve block, study medication dosage and number of legs in the group:
Group A: PPB with 10 ml of lidocaine 1%, 20 legs.
Group B: PPB with 20 ml of lidocaine 1%, 20 legs.
Group C: PPB with 30 ml of lidocaine 1%, 20 legs.
Group FNB: FNB with 20 ml of lidocaine 1%, 10 legs.
Group SNB: SNB with 20 ml of lidocaine 1%, 10 legs.
Masking
ParticipantInvestigatorOutcomes Assessor
Masking Description
As different volumes are used for the nerve blocks, the anesthesiologist and an assistant performing the nerve blocks will not be blinded, and therefore have no further contact with the volunteers after the nerve block performance and will not contribute with the data collection or statistical analysis. The nerve block procedure and assessments will take place in different rooms; hence the data collecting assessors will not be present during block performance.To ensure blinding of the volunteer, a draping will hinder the volunteer from observing which volume of lidocaine that is administered during block performance.Group A, B and C are blinded until the data analysis is finished. Group FNB of SNB are unblinded and works as active comparatives for model control, in order to establish reference points for when a nerve is considered affected.
Allocation
Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Group A
Arm Type
Experimental
Arm Description
Popliteal Plexus Block given with 10 ml of Lidocaine Hydrochloride 10 mg/ml
Arm Title
Groups B
Arm Type
Experimental
Arm Description
Popliteal Plexus Block given with 20 ml of Lidocaine Hydrochloride 10 mg/ml
Arm Title
Group C
Arm Type
Experimental
Arm Description
Popliteal Plexus Block given with 30 ml of Lidocaine Hydrochloride 10 mg/ml
Arm Title
Group FNB
Arm Type
Active Comparator
Arm Description
Femoral Nerve Block given with 20 ml of Lidocaine Hydrochloride 10 mg/ml
Arm Title
Groups SNB
Arm Type
Active Comparator
Arm Description
Sciatic Nerve Block given with 20 ml og Lidocaine Hydrochloride 10 mg/ml
Intervention Type
Drug
Intervention Name(s)
Lidocaine Hydrochloride 10 MG/ML [Xylocaine]
Other Intervention Name(s)
Popliteal Plexus Block
Intervention Description
Ultrasound-guided Popliteal Plexus Block using 10 ml of of Lidocaine Hydrochloride 10 mg/ml
Intervention Type
Drug
Intervention Name(s)
Lidocaine Hydrochloride 10 MG/ML [Xylocaine]
Other Intervention Name(s)
Popliteal Plexus Block
Intervention Description
Ultrasound-guided Popliteal Plexus Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml
Intervention Type
Drug
Intervention Name(s)
Lidocaine Hydrochloride 10 MG/ML [Xylocaine]
Other Intervention Name(s)
Popliteal Plexus Block
Intervention Description
Ultrasound-guided Popliteal Plexus Block using 30 ml of of Lidocaine Hydrochloride 10 mg/ml
Intervention Type
Drug
Intervention Name(s)
Lidocaine Hydrochloride 10 MG/ML [Xylocaine]
Other Intervention Name(s)
Femoral Nerve Block
Intervention Description
Ultrasound-guided Femoral Nerve Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml. Is used to find cut-off values that define affection of the femoral nerve.
Intervention Type
Drug
Intervention Name(s)
Lidocaine Hydrochloride 10 MG/ML [Xylocaine]
Other Intervention Name(s)
Sciatic Nerve Block
Intervention Description
Ultrasound-guided Sciatic Nerve Block using 20 ml of of Lidocaine Hydrochloride 10 mg/ml. Is used to find cut-off values that define affection of the sciatic nerve.
Primary Outcome Measure Information:
Title
MVIC (Maximum Voluntary Isometric Contraction) ankle plantarflexion
Description
Difference between group A, B and C in post block MVIC by ankle plantarflexion, expressed as percentage change of the pre block value. MVIC is measured using a handheld dynamometer.
Time Frame
Measured pre block and at 60 minutes post block
Title
MVIC ankle dorsiflexion
Description
Difference between group A, B and C in post block MVIC by ankle dorsiflexion, expressed as a percentage change of the pre block value. MVIC is measured using a handheld dynamometer.
Time Frame
Measured pre block and at 60 minutes post block
Secondary Outcome Measure Information:
Title
MVIC knee extension
Description
Difference between group A, B and C in post block MVIC by knee extension, expressed as a percentage change of the pre block value. MVIC is measured using a handheld dynamometer.
Time Frame
Measured pre block and at 60 minutes post block
Title
cMAP (compoud motor action potention) gatrocnemius
Description
Difference between group A, B and C, in the number of volunteers with affected cMAP of the gastrocnemius muscle, defined as sufficient change from pre block to post block. Cut-off value for sufficient change is determined by SNB group. cMAP is recorded using a motor nerve conduction study.
Time Frame
Measured pre block and at 60 minutes post block
Title
cMAP tibialis anterior
Description
Difference between group A, B and C, in the number of volunteers with affected cMAP of the tibialis anterior muscle, defined as sufficient change from pre block to post block. Cut-off value for sufficient change is determined by SNB group. cMAP is recorded using a motor nerve conduction study.
Time Frame
Measured pre block and at 60 minutes post block
Title
cMAP vastus medialis
Description
Difference between group A, B and C, in the number of volunteers with affected cMAP of the vastus medialis muscle, defined as sufficient change from pre block to post block. Cut-off value for sufficient change is determined by FNB group. cMAP is recorded using a motor nerve conduction study.
Time Frame
Measured pre block and at 60 minutes post block
Title
cMAP vastus lateralis
Description
Difference between group A, B and C, in the number of volunteers with affected cMAP of the vastus lateralis muscle, defined as sufficient change from pre block to post block. Cut-off value for sufficient change is determined by FNB group. cMAP is recorded using a motor nerve conduction study.
Time Frame
Measured pre block and at 60 minutes post block
Title
Saphenus senory test
Description
Difference between group A, B and C in the number of volunteers with an affected sensory of the saphenous nerve, defined as change, from pre block to post block, in the volunteers ability to discriminate cold in the cutaneous area innervated by the medial crural cutaneous branches of saphenous nerve.
Time Frame
Measured pre block and at 60 minutes post block
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
ASA 1-2
Ability to give their written informed consent to participating in the study after having fully understood the contents of the study
Exclusion Criteria:
Subjects who cannot cooperate with the study.
Subjects who cannot understand or speak Danish.
Subjects with allergy to the medicines used in the study.
Subjects suffering from alcohol and/or drug abuse - based on the investigator's opinion.
Pathology or previous surgery to the lower limb.
Intake of any analgesics 24 hours prior to baseline measurements.
BMI > 30
Pregnancy status, provided by the volunteer.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Johan Sørensen, MD
Phone
+4528945356
Email
joksoe@rm.dk
First Name & Middle Initial & Last Name or Official Title & Degree
Charlotte Runge, MD
Phone
+4525883172
Email
charlotte.runge@aarhus.rm.dk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Johan Sørensen, MD
Organizational Affiliation
Aarhus Universitet (Aarhus)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Elective Surgery Center at Silkeborg Regional Hospital
City
Silkeborg
State/Province
Region Midt
ZIP/Postal Code
8600
Country
Denmark
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Johan Sørensen, MD
Phone
+4528945356
Email
joksoe@rm.dk
First Name & Middle Initial & Last Name & Degree
Charlotte Runge, MD
Phone
+4525883172
Email
charlotte.runge@aarhus.rm.dk
First Name & Middle Initial & Last Name & Degree
Johan Sørensen, MD
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Data will be shared after acceåtance from The Danish Data Protection Agency
IPD Sharing Time Frame
At the end of the study analysis
IPD Sharing Access Criteria
Permission by investigators
Learn more about this trial
The Effect of PPB Using 10, 20 and 30 ml of Lidocaine, Study on Volunteers
We'll reach out to this number within 24 hrs